Serum beta 2-microglobulin and interferon in homosexual males: relationship to clinical findings and serologic status to the human T lymphotropic virus (HTLV-III).

Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

Serum beta 2-microglobulin and interferon in homosexual males: relationship to clinical findings and serologic status to the human T lymphotropic virus (HTLV-III).

AIDS Res. 1984-85;1(6):423-38. Unique Identifier : AIDSLINE MED/86242473
Calabrese LH; Proffitt MR; Gupta MK; Easley KA; Walker JR; Rehm SJ; Valenzuela R; Clough JD

Abstract: The identification of the human T cell lymphotropic virus (HTLV-III) as the presumed etiologic agent for AIDS has stimulated a re-examination and allowed better understanding of many of the immunologic abnormalities described in high risk individuals with and without clinical disease. Currently needed are useful predictors of clinical progression which will allow better counselling, earlier diagnosis and effective treatment of high risk individuals. We have examined the principles of test selection including sensitivity, specificity, predictive value and overall test efficiency for serum beta 2 microglobulin (beta 2M), serum interferon (IFN) and antibody to HTLV-III (HTLV-III Ab) in a group of 113 homosexual men and 62 controls. The presence of HTLV-III Ab and elevated serum beta 2M appear to be the most sensitive markers of immune dysregulation in the study group but also proved to be the least specific. Rising levels of serum beta 2M correlated with clinical severity where HTLV-III Ab positivity did not. The detection of elevated levels of acid labile serum IFN alpha was most specific for full-blown AIDS and was overall the most efficient test when compared with HTLV-III Ab, serum beta 2M and lymphocyte subpopulations. We believe that further examinations of the principles of test selection for immunologic abnormalities in AIDS may lead to potential applications for these tests in patient management.

Keywords: beta 2-Microglobulin/*ANALYSIS/PHYSIOLOGY Acquired Immunodeficiency Syndrome/*BLOOD/IMMUNOLOGY Antibodies, Monoclonal/DIAGNOSTIC USE Antibodies, Viral/*ANALYSIS/IMMUNOLOGY Fluorescent Antibody Technique *Homosexuality Human HTLV-BLV Viruses/*IMMUNOLOGY Interferon Type I/BLOOD Interferon Type II/BLOOD Interferons/*BLOOD/PHYSIOLOGY Male Support, Non-U.S. Gov't T-Lymphocytes, Cytotoxic/IMMUNOLOGY T-Lymphocytes, Helper-Inducer/IMMUNOLOGY JOURNAL ARTICLE

861030
M86A0288

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .